Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3352W HIGH $20.35
Volume
657.45 K
Value Traded
269.98 K
Short % Float
6.19%
-23.67%Week
-40.57%1 Month
+575.1%3 Month
+48.58%6 Month
-99.38%5 Year
-99.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.84 M
EPS (TTM)
-25.28
P/E Ratio
-
Ent. Value
408.76 K
Total Shares
600.74 K
Float Shares
1.15 M
Insiders
1.62%
Institutions
5.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BIAF Catalyst Timeline
Dated clinical, regulatory and corporate events for bioAffinity Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for bioAffinity Technologies, Inc.
208Total events
11Upcoming
23Tier-1 (high impact)
2022 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Closing of $4 million registered direct financing of common stock and concurrent private placement
▲Patent GrantedIP / Competition
Japan Patent Office issues Notice of Allowance for CyPath Lung patent
early-stage lung cancersource ↗
▼Equity OfferingCorporate
bioAffinity prices ~$4M registered direct offering of common stock plus concurrent private placement of warrants
●Poster PresentationPresentation
bioAffinity presents CyPath Lung to healthcare leaders at GO2 for Lung Cancer Centers of Excellence Lung Cancer Screening and Care Conference
lung cancersource ↗
▲Partnership / LicenseCorporate
bioAffinity and AvMEDICAL debut joint exhibition of CyPath Lung under new distribution agreement at NAVREF 2026
lung cancersource ↗
▲Patent GrantedIP / Competition
Hong Kong Intellectual Property Department granted patent HK40048460 for CyPath Lung platform technology
lung cancersource ↗
▲R&D DayPresentation
bioAffinity presented CyPath Lung at GO2 for Lung Cancer Centers of Excellence Lung Cancer Screening and Care Conference in San Diego
lung cancersource ↗
▲Partnership / LicenseCorporate
bioAffinity enters nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung
lung cancersource ↗
▲Partnership / LicenseCorporate
Distribution agreement with AvMEDICAL for CyPath Lung
lung cancersource ↗
▼Equity OfferingCorporate
Closing of $4M private placement of pre-funded warrants and warrants
▼Equity OfferingCorporate
Pricing of $4M private placement offering of common stock and warrants
▲Patent GrantedIP / Competition
Mexican Institute of Industrial Property allows patent application for sputum labeling and flow cytometry
▲Partnership / LicenseCorporate
Collaboration with Pictor, Inc. to support development of next-generation diagnostic tests for asthma and COPD
asthma and COPDsource ↗
▲Preclinical PoCPreclinical
Positive preliminary therapeutic data support development of topical treatments for skin cancers
squamous and basal cell skin cancerssource ↗
▲Oral PresentationPresentation
Presented positive research results on diagnostic platform for matching patients with biologic therapies
asthma and COPDsource ↗
●PublicationPresentation
Published comprehensive clinical review and white paper on CyPath Lung
lung cancersource ↗
●PublicationPresentation
Publication of clinical review and white paper on CyPath® Lung
lung cancersource ↗
▲Partnership / LicenseCorporate
bioAffinity Technologies and Pictor partner to develop and commercialize diagnostics for asthma and COPD
asthma and COPDsource ↗
▲Quarterly UpdateCorporate
CyPath Lung Q2 2026 sales more than doubled year-over-year and increased >30% sequentially
▲Quarterly UpdateCorporate
CyPath Lung sales increased more than 100% through Q3 2026 vs 2025
lung cancersource ↗
▲Preclinical PoCPreclinical
Positive preliminary therapeutic data support development of topical treatments for skin cancers
squamous and basal cell skin cancerssource ↗
▲Platform ValidationPreclinical
Positive research results presented for diagnostic platform to identify antibody drug receptors in sputum
asthma and COPDsource ↗
▲Partnership / LicenseCorporate
Announced collaboration with Pictor, Inc. for next-generation diagnostic tests
asthma and COPDsource ↗
▲Patent GrantedIP / Competition
Received notice of allowance from Mexican Institute of Industrial Property for patent application
lung cancersource ↗
▼Equity OfferingCorporate
bioAffinity completes public offering generating approximately $3.2 million in gross proceeds
●Oral PresentationPresentation
SAB and NAVREF hosted webinars featuring CyPath Lung
lung cancersource ↗
●PublicationPresentation
Published comprehensive clinical review and white paper on CyPath Lung
lung cancersource ↗
▲Poster PresentationPresentation
Presented positive research results for diagnostic platform to identify antibody drug receptors in sputum
asthma and COPDsource ↗
▲Trial InitiationTrial
Longitudinal clinical trial for CyPath Lung begins patient enrollment at 11 clinical sites
lung cancersource ↗
▲Preclinical PoCPreclinical
Positive preclinical findings for proprietary gene silencing technology in squamous skin cancer cells
squamous skin cancersource ↗
▲Partnership / LicenseCorporate
bioAffinity Technologies, Philips, and 4DMedical announce program to advance veteran lung health screening
lung health screeningsource ↗
◆Enrollment UpdateTrial
Enrollment of 30-50 patients for deep suction validation study
lung cancersource ↗
▲Patent GrantedIP / Competition
Mexico patent allowance for CyPath Lung flow cytometry methods
lung cancersource ↗
◆Oral PresentationPresentation
CyPath Lung featured at Cleveland Clinic Advances in Early Lung Cancer Detection symposium; CMO participates in panel
lung cancersource ↗
◆Oral PresentationPresentation
CyPath® Lung in Practice: A Physician Roundtable Discussion
lung cancersource ↗
▲Oral PresentationPresentation
New case study published showing CyPath Lung provided actionable results and helped patient avoid invasive procedures
lung cancersource ↗
▲Trial InitiationTrial
Initiation of large-scale longitudinal clinical study for CyPath Lung
lung cancersource ↗
●Poster PresentationPresentation
Poster presentation at AAAAI 2026 annual meeting on sputum diagnostic for asthma/COPD
asthma, COPDsource ↗
Past FDA Catalysts and PDUFA Decisions
How BIAF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BIAF program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zannes MariaOfficer (President & CEO) | Option | 64,848 229,506 held | $1.16 | 04/08/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in BIAF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BIAF for Q2 2026. | ||||
BIAF Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIAF ranks across every disease it competes in
Competitive Position is a premium feature
See how BIAF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIAF News
BIAF▼ -16.3%today
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. has successfully completed a registered direct offering, raising approximately $4 million. The financing included shares of common stock and warrants, with proceeds intended for working capital and to support the sales growth of its noninvasive lung cancer test, CyPath® Lung. WallachBeth Capital acted as the sole placement agent for this offering.
Read more →BIAF▼ -16.3%today
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. has successfully closed a $4 million registered direct financing of common stock. This financing was conducted under Nasdaq rules and includes a concurrent private placement. The move is expected to strengthen the company's financial position.
Read more →BIAF▼ -10.8%on this news· ran to -25% by day 1shared move
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies has entered into a definitive agreement for a registered direct offering, selling shares at $6.122 each, alongside a concurrent private placement for warrants. The expected gross proceeds are around $4 million, aimed at supporting the company's noninvasive lung cancer test, CyPath® Lung. The offering is set to close on or about October 9, 2026, pending customary conditions.
Read more →BIAF▼ -30.8%on this news· ran to -42% by day 1shared move
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. has announced a registered direct financing of approximately $4 million in common stock. This financing is priced at-the-market under Nasdaq rules, indicating a strategic move to enhance its financial position. The concurrent private placement further supports the company's growth initiatives.
Read more →BIAF▼ -8.4%on this news· ran to -23% by day 1shared move
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
bioAffinity Technologies has announced the receipt of a patent allowance in Japan for its CyPath Lung diagnostic test, which is a noninvasive method for detecting lung cancer. This patent is a significant milestone for the company, enhancing its position in the lung cancer diagnostic market. The CyPath Lung test utilizes advanced technology to improve patient outcomes.
Read more →BIAFbioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
bioAffinity Technologies reported a significant increase in sales of its CyPath® Lung test, with over 100% growth through the third quarter of 2026 compared to the previous year. This growth indicates a rising clinical adoption of the test, which is designed for the early detection and monitoring of lung cancer in high-risk individuals. The company's focus on noninvasive healthcare solutions is contributing to its success in the market.
Read more →BIAFbioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
bioAffinity Technologies has partnered with AvMEDICAL to promote its noninvasive CyPath Lung cancer test, specifically targeting veteran awareness. The new distribution agreement was showcased for the first time at the NAVREF 2026 Annual Conference. This collaboration aims to enhance access to lung cancer testing for veterans.
Read more →BIAF▲ +11.1%on this news
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
bioAffinity Technologies is set to present two posters on the CyPath Lung diagnostic test at the 2026 NAVREF Annual Conference. The data presented will focus on both clinical outcomes and veteran-specific insights, highlighting the test's potential in lung cancer diagnostics. This event marks a significant opportunity for the company to showcase its advancements in the field.
Read more →BIAF▲ +63.6%on this news· ran to +76% by day 1shared move
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
bioAffinity Technologies has announced the grant of a new patent in Hong Kong for its CyPath Lung diagnostic technology, which is designed for noninvasive lung cancer detection. This patent protects the proprietary technology, enhancing the company's competitive edge in the lung cancer diagnostic market. The development signifies a positive step forward for bioAffinity in improving patient care.
Read more →BIAF▲ +17.6%on this news
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies has announced that it has regained compliance with Nasdaq's listing requirements. This development allows the company to maintain its listing status and continue its operations on the exchange. The news is expected to positively impact investor confidence and the company's market position.
Read more →BIAF▲ +19.5%on this news· ran to -30% by day 1
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
bioAffinity Technologies will be represented by President and CEO Maria Zannes at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14 to 16, providing a platform for the company to present a corporate update.
Read more →BIAF▲ +44.5%on this news· ran to +235% by day 3shared move
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
bioAffinity Technologies is advancing its CyPath® Lung test for monitoring lung cancer survivors post-treatment. This noninvasive test aims to complement imaging methods by providing critical information on potential malignancies. Clinical trials indicate its effectiveness in early-stage lung cancer detection, potentially leading to improved patient outcomes. However, its validation for post-treatment use remains pending.
Read more →BIAFbioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
bioAffinity Technologies has announced a 1-for-15 reverse stock split of its common stock. This action will take effect at the opening of trading on Nasdaq on August 24, 2026. The move aims to improve the stock's marketability and potentially attract more institutional investors.
Read more →BIAF▲ +20.7%on this newsshared move
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
bioAffinity Technologies has announced a distribution agreement with AvMEDICAL to enhance the sales reach of its CyPath Lung product. This agreement aims to improve access to government healthcare systems, indicating a strategic move to expand market presence. The collaboration is expected to facilitate broader distribution and increase visibility in federal healthcare channels.
Read more →BIAFWallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies has successfully closed a $4 million private placement offering priced at-the-market under Nasdaq rules. The offering involves pre-funded warrants for the purchase of approximately 8.46 million shares of common stock. The proceeds will support the company's initiatives in noninvasive diagnostics and early cancer detection. WallachBeth Capital acted as the sole placement agent for this transaction.
Read more →BIAFbioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies has successfully closed a $4 million private placement offering. The offering was priced at-the-market in compliance with Nasdaq regulations. This funding is expected to support the company's ongoing initiatives and growth strategies.
Read more →BIAF▼ -14.6%on this newsshared move
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
WallachBeth Capital has announced that bioAffinity Technologies will raise approximately $4 million through a private placement offering. The deal includes the sale of over 8 million shares and warrants, priced at-the-market under Nasdaq rules. The offering is expected to close shortly, pending customary conditions. This funding aims to support bioAffinity's focus on noninvasive diagnostics and early cancer detection.
Read more →BIAF▼ -19%on this newsshared move
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies has announced the pricing of a $4 million private placement offering. This offering is priced at-the-market in accordance with Nasdaq rules, indicating a strategic move to raise capital. The funds raised are expected to support the company's ongoing operations and initiatives.
Read more →BIAFbioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
bioAffinity Technologies has announced its financial results for the second quarter of 2026, highlighting continued commercial success for its CyPath® Lung test, which is designed for lung cancer detection. The report indicates a positive trajectory in both sales and market presence. This momentum suggests growing recognition and demand for the company's innovative diagnostic solutions.
Read more →BIAFbioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
bioAffinity Technologies has published a white paper detailing new clinical protocols for evaluating lung nodules and enhancing patient care for lung cancer survivors. This initiative aims to improve early detection of lung cancer and addresses the increasing demand for effective risk stratification in this area. The publication is part of their CyPath® Lung framework.
Read more →About bioAffinity Technologies, Inc.
Headquarters3300 NACOGDOCHES ROAD, SAN ANTONIO, TX, 78217
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next BIAF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime